advanced renal cell carcinoma
Conditions
Interventions
Oral administration of molecular targeted therapeutic drug (standard treatment) group Observation period: 2 weeks
Molecular targeted therapeutic agent + 3 g of Koujin powder with 9 g of Ninjin-youeit
Sponsors
Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Of adult Japanese, patients diagnosed with advanced renal cancer 2) 1)), FACIT-f's "fatigue is present" among patients with molecular targeted drugs (brand name: Sutent, Votiento, Inirita) who have fatigue and fatigue as side effects Two or more patients each "feel tired" items 3) After receiving sufficient explanation for the participation of this study, patients who gained document consent by the patient's free will with sufficient understanding
Exclusion criteria
Exclusion criteria: 1) Patients who can not ingest ginseng preparations 2) Patients who have allergies to traditional Chinese medicine 3) Patients who are pregnant, have a possibility of pregnancy, are within 28 days after birth, or who are breastfeeding 4) Patients with fatigue of CTC-AE grade 3 or higher, which is the criterion for terminating molecular targeted therapeutic drugs 5) Patients who recognize the rapid progress of disease 6) Patients taking steroids, Chinese medicines and ginseng preparations, other supplements supposedly effective for fatigue within 1 month 7) Patients with hypothyroidism (FT4 0.7 or lower), patients with advanced anemia (HGB decreases by 2 or more in one month) 8) Advanced renal dysfunction, daily urine volume reduction cases 9) Patients who are judged inappropriate for the study responsible doctor or the test sharing doctor to safely carry out this test
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT - F), score the degree of fatigue / fatigue before and 2 weeks after administration of ginseng preparation and evaluate the change. | — |
Countries
Japan
Contacts
Public ContactTomokazu Sazuka
Chiba University Urology
Outcome results
None listed